Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Receptor Occupancy Study of TS-121 in Healthy Men
NCT02448212Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- May 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ANC-501 in major depressive disorder (MDD) (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Positron emission tomography measure (receptor occupancy) at Day 3. Started May 2015; status: completed.
02
Drugs
ANC-501
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02448212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02448212.